|Bid||106.38 x 100|
|Ask||142.00 x 100|
|Day's Range||135.50 - 137.83|
|52 Week Range||96.18 - 145.42|
|PE Ratio (TTM)||64.64|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Immunomedics (IMMU) was a big mover last session, as the company saw its shares rise over 5% on the day amid huge volumes.
Key highlights include regulatory approvals for companies like Alexion (ALXN) and Ironwood while Biogen is one of the companies facing an investigation into the pricing of multiple sclerosis drugs.
Incyte reported revenues of ~$326.4 million for 2Q17, compared with ~$246.3 million for 2Q16.